Skip to Content

Lyumjev Approval History

FDA Approved: Yes (First approved June 15, 2020)
Brand name: Lyumjev
Generic name: insulin lispro-aabc
Dosage form: Injection
Company: Eli Lilly and Company
Treatment for: Diabetes, Type 1, Diabetes, Type 2

Lyumjev (insulin lispro-aabc) is a rapid-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus.

  • Lyumjev (insulin lispro-aabc) is a novel formulation of insulin lispro, which is marketed as Humalog.
  • Lyumjev 100 units/mL (U-100) injection is available as multiple-dose vials, and single-patient-use prefilled pens and cartridges. Lyumjev 200 units/mL (U-200) injection is available as multiple-dose vials.
  • Lyumjev is administered subcutaneously into the abdomen, upper arm, thigh, or buttocks at the start of a meal, or within 20 minutes after starting a meal. Lyumjev (U-100) is administered intravenously only under medical supervision.
  • Side effects include hypoglycemia, injection site reactions, allergic reactions, rash, pruritus, lipodystrophy, and weight gain.

Development History and FDA Approval Process for Lyumjev

DateArticle
Jun 15, 2020Approval FDA Approves Lyumjev (insulin lispro-aabc injection) for Type 1 and Type 2 Diabetes

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.